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Abbreviations:  
ALT, alanine aminotransferase;  
AST, aspartate aminotransferase; 
AUC, area under the curve;  
CCl4, carbon tetrachloride;  
CV, central vein; 
DMSO, dimethyl sulfoxide;  
DNA, deoxyribonucleic acid;  
ELISA, enzyme-linked immunosorbent assay;  
FFA, free fatty acid;  
GSTs, glutathione S-transferases;  
HE, haematoxylin and eosin staining; 
HF, high-fat;  
IL-6, interleukin-6;  
ITT, Insulin tolerance test;  
LXR, liver X receptor;  
MCD, methionine-/choline-deficient;  
MT, masson’s trichrome staining; 
NAFLD, non-alcoholic fatty liver disease;  
NAS, NAFLD activity scores;  
NASH, non-alcoholic steatohepatitis;  
OR, oil red O staining; 
PBS, phosphate buffered salts;  
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PV, portal vein;  
RNA, ribonucleic acid;  
ROS, reactive oxygen species;  
RT-PCR, reverse transcription polymerase chain reaction;  
SLR, soluble leptin receptor;  
SR, sirius red staining; 
T-CHO, total cholesterol;  
TG, triglyceride;  
TNF-α, tumour necrosis factor alpha;  
VLDL, very-low-density lipoprotein.  
  
4 
 
1. Introduction 
 
Metabolic syndrome has been increasing worldwide concomitant with the increased 
prevalences of obesity, diabetes mellitus, and hyperlipidaemia. Non-alcoholic fatty liver disease 
(NAFLD) was recently recognized as a hepatic manifestation of metabolic syndrome.1 NAFLD 
consists of simple hepatic steatosis and NASH.2 NASH is diagnosed using only histopathological 
findings, i.e., hepatic steatosis, ballooning hepatocytes, lobular inflammation and perisinusoidal 
fibrosis. Currently, NAFLD is present in 20-40% of the general population of industrialized 
countries.3,4 Among all patients with NAFLD, features of NASH are observed in 10-20%.5,6 
Thus, NAFLD is considered a common chronic liver disease. Because studies of NASH using 
human materials are limited by ethical concerns regarding the administration of drugs to patients 
or the collection of liver tissues from patients, the pathogenesis of NASH is currently not well 
understood, and treatments for NASH have not been established. 
In recent years, many experimental NASH models have been reported.7-11 However, there 
are few models which reflect to the features of human NASH i.e., both pathological findings and 
insulin resistance. The methionine-/choline-deficient (MCD) model has been widely used for 
basic studies of NASH.12 The advantage of the MCD model is that it can rapidly induce 
steatohepatitis in mice. After three weeks of MCD feeding, steatohepatitis is well developed, and 
after 8-10 weeks, pericellular and perisinusoidal fibroses are present.13 The disadvantages of this 
model are that the mice exhibit a dramatic body weight loss and do not develop insulin 
resistance.13,14 As a result, these features of the MCD model do not fully reflect the clinical 
features of human NASH. 
A high-fat (HF) diet model is also widely used for the basic study of NASH because it 
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causes obesity and insulin resistance.15 In the HF diet models, long-term feeding of a HF diet 
leads to steatohepatitis that resembles that observed in human NASH.16 However, this model is 
not suitable for researching the pathogenesis of NASH because a long time is required for the 
development of NASH symptoms and because the hepatic fibrosis in the model animals is 
weaker than that found in human NASH.16 Therefore, the establishment of a novel animal model 
that exhibits features similar to those of human NASH is necessary for the basic study of NASH. 
I aimed to develop a novel NASH model by feeding an HF diet and administering both 
carbon tetrachloride (CCl4) and T0901317, which resulted in a combination of multiple 
important factors, including overnutrition, oxidative stress and lipogenesis. The administration of 
CCl4 is known to induce chronic oxidative stress and liver injury in mice, and CCl4 has been 
used to create acute hepatitis animal models.17 An analysis of histopathological findings has 
revealed that CCl4 leads to inflammation and fibrosis but not steatosis or ballooning. The liver X 
receptor (LXR) is a nuclear receptor that plays a key role in regulating cholesterol, fatty acid and 
glucose metabolism.18 The LXR activator T0901317 has been recognized as a potential target for 
the treatment of atherosclerosis. However, T0901317 produces several severe side effects, 
including hepatic steatosis.18 
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2. Aim of research 
 
The aim of this study was to establish a novel NASH model with histopathological and 
insulin-resistance features similar to those of human NASH. 
 
3. Materials and methods 
 
3-1. Animals 
Six-week-old male C57BL/6J mice were obtained from Charles River Laboratories 
JAPAN, Inc. (Kanagawa, Japan) and were acclimated for one week before the start of the 
experiment. The mice were maintained under a 12 h light-dark cycle and had free access to 
standard chow and tap water. The animal experiments were conducted in a humane manner after 
receiving approval from the Institutional University Experiment Committee of the University of 
Tsukuba and in accordance with the Regulations for Animal Experiments of the university and 
Fundamental Guidelines for Proper Conduct of Animal Experiment and Related Activities in 
Academic Research Institutions under the jurisdiction of the Ministry of Education, Culture, 
Sports, Science, and Technology. 
 
3-2. Experimental groups 
Twenty mice were divided into the following four groups (n = 5 per group). All mice 
were kept to feed HF diet from day 0 to day 25 (about four weeks). 
(i) the mice in the HF group were fed an HF diet (60 kcal% fat, D12492, Research Diets, Inc., 
New Brunswick, NJ, USA) for 25 days. 
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(ii) the mice in the HF + CCl4 group were fed an HF diet for 25 days and administered CCl4 
(Wako Pure Chemical Industries, Ltd., Osaka, Japan) intraperitoneally twice a week for the final 
two weeks (day 14, 17, 21 and 24). 
(iii) the mice in the HF + T0901317 group were fed an HF diet for 25 days and administered 
T0901317 (Cayman Chemical Co., Ann Arbor, MI, USA) solubilized in DMSO intraperitoneally 
once a day for the final five days (from day 20 to day 24). 
(iv) the mice in the novel NASH model group were fed an HF diet for 25 days and administered 
both CCl4 and T0901317, as described above. The protocol of novel NASH model was shown in 
Figure 1. The CCl4 dose was diluted with corn oil to 0.1 mL/kg, and the T0901317 dose was 
diluted with a solvent diluted 1:1 with DMSO and PBS to 2.5 mg/kg. 
Twenty-four hours after the final administration of CCl4 or T0901317, the mice were 
sacrificed by exsanguination under isoflurane anaesthesia. Blood samples were collected from 
the orbital capillary and centrifuged at 3,000 rpm for 10 min to isolate the serum. Each sample 
was stored at -30°C until analysis. The liver was rapidly removed and weighed. The right medial 
lobe of the liver was immediately fixed in 10% neutral-buffered formalin for further histological 
examination. 
 
3-3. Histological analysis 
The fixed liver tissues were processed and embedded in paraffin using standard methods. 
The liver tissues were assessed by cutting into 2-μm-thick paraffin sections, staining with 
haematoxylin and eosin, and evaluating the extent of inflammation and hepatocellular 
ballooning. Fibrosis was evaluated by Masson’s trichrome and Sirius red staining. Steatosis was 
evaluated by Oil Red O staining. The steatosis area was quantified using a BZ-X710 hybrid cell 
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count system (KEYENCE, Corp., Osaka, Japan). For each section, at least ten non-consecutive 
random digital images were obtained. The liver specimens were evaluated by an experienced 
pathologist in a blinded fashion, and the severity of hepatocellular steatosis, inflammation and 
ballooning was assessed using the following NAFLD activity scores (NAS). With respect to 
hepatocellular steatosis, the specimens were classified into grades 0-3 (grade 0: steatosis 
occupied less than 5% of the hepatic parenchyma; grade 1: steatosis occupied 6-33% of the 
hepatic parenchyma; grade 2: steatosis occupied 34-66% of the hepatic parenchyma; and grade 
3: steatosis occupied more than 66% of the hepatic parenchyma). In terms of inflammatory cell 
infiltration, the specimens were classified as grades 0-3 (grade 0: no infiltration; grade 1: one to 
two foci per 200× field; grade 2: three to four foci per 200× field; and grade 3: more than four 
foci per 200× field). With respect to hepatocellular ballooning, the specimens were classified into 
grades 0-2 (grade 0: no ballooning; grade 1: few balloon cells; and grade 2: many 
cells/prominent ballooning). Hepatic fibrosis was assessed using the following Kleiner 
classification (stage 0: no fibrosis; stage 1: mild, perisinusoidal or periportal fibrosis; stage 2: 
moderate, perisinusoidal and periportal fibrosis; stage 3: bridging fibrosis; and stage 4: 
cirrhosis).19 
 
3-4. Biochemical analysis 
The serum levels of aspartate aminotransferase (AST), alanine aminotransferase (ALT), 
triglyceride (TG), and total cholesterol (T-CHO) were measured with a FUJI DRI-CHEM 7000 V 
serum multiple biochemical analyser (Fujifilm, Co. Tokyo, Japan). 
The serum levels of tumour necrosis factor alpha (TNF-α) and interleukin-6 (IL-6) were 
measured using a mouse enzyme-linked immunosorbent assay (ELISA) kit (BioLegend, Inc., 
9 
 
San Diego, CA, USA). 
 
3-5. Insulin tolerance test (ITT) 
Four groups of mice subjected to the same regimen (n=5 per group) were assessed using 
the ITT. The mice were fasted for 4 h before the injection of insulin (Humulin R, 0.75 U/kg, i.p.; 
Eli Lilly, Co., Kobe, Japan). The blood glucose levels in the tail vein blood were measured 0, 15, 
30, 60, 90 and 120 min after the insulin injection. The blood glucose levels at the 0 min was 
taken as 100%, and the change rate of blood glucose levels at each point from 0 min was 
evaluated. 
 
3-6. Gene expression analysis 
Liver tissue samples were freshly collected and immediately frozen at -30°C until use. 
The frozen liver samples were homogenized, and total RNA was isolated from whole cells using 
a NucleoSpin® RNA kit (Takara Bio, Inc., Otsu, Japan). The RNA concentrations were 
determined by measuring the absorbance at 260/280 nm with a NanoDrop Spectrophotometer 
(Thermo Fisher Scientific, Inc., Wilmington, DE, USA). The synthesis of complementary DNA 
was performed using AMV Reverse Transcriptase (Promega, Corp., Madison, WI, USA) and 
random primers (Takara Bio, Inc. Otsu, Japan). Briefly, a mixture of 1 mM dNTPs (Fermentas 
Life Sciences, Inc., Burlington, ON, Canada), 0.025 μg/ml random primers, 0.25 U/ml reverse 
transcriptase, and 500 ng of total RNA was incubated at 30°C for 10 min, 37°C for 60 min, 95°C 
for 5 min and at 4°C prior to storage at -80°C. 
The primers for RT-PCR were designed using Primer Express software for Real-Time 
PCR ver. 3.0 (Applied Biosystems, Inc., Foster City, CA, USA) based on the sequences available 
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in GenBank. The primers were purchased from Hokkaido System Science Co., Ltd. (Hokkaido, 
Japan) and Takara Bio, Inc. (Otsu, Japan). The Srebp-1c primer sequences were 5’-
GCAGCCACCATCTAGCCTG-3’ and 5’-CAGCAGTGAGTCTGCCTTGAT-3’. The Fas primer 
sequences were 5’-GGAGGTGGTGATAGCCGGTAT-3’ and 5’-
TGGGTAATCCATAGAGCCCAG-3’, and the ApoB primer sequences were 5’-
TTGGCAAACTGCATAGCATCC-3’ and 5’-TCAAATTGGGACTCTCCTTTAGC-3’. The 
Gstm3 primer sequences were 5’-CATCCGCTTGCTCCTGGAATA-3’ and 5’-
GATGGCATTGCTCTGGGTGA-3’. The Scd1 primer sequences were 5’-
TGTCTGACCTGAAAGCCGAGAA-3’ and 5’-AGCACCAGAGTGTATCGCAAGAA-3’. The 
Scd2 primer sequences were 5’-GCTGCATTTGGGAGCCTTGTA-3’ and 5’-
CCATGGTGTTGGCAATGATGA-3’. The Ly6d primer sequences were 5’-
AGCTCTGCTCGTCCTCCTTGTC-3’ and 5’-TCCTCACCAGGTTCCCATTCA-3’, and the 
Lepr primer sequences were 5’-GGCACCATTTCCGCTTCAATA-3’ and 5’-
ACCAGCAGAGATGTAGCTGAGACAA-3’, and the GAPDH primer sequences were 5’-
TGCATCCTGCACCACCAACT-3’ and 5’-AACACGGAAGGCCATGCCAG-3’. 
Glyceraldehyde-3-phosohate dehydrogenase (GAPDH) was used as an endogenous control. RT-
PCR was performed using SYBR-Green Real-time PCR Master Mix-Plus (Toyobo Co., Ltd., 
Osaka, Japan) and an Applied Biosystems 7300 Real-time PCR system (Applied Biosystems, 
Inc., Foster City, CA, USA) as recommended by the manufacturers.20 
 
3-7. Microarray analysis 
A DNA microarray analysis was conducted using RNA samples isolated from liver 
tissues from the HF group and the novel NASH model group. Labelled cRNA was synthesized 
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from 100 ng of total RNA using a GeneChip® 3’ IVT Plus Reagent Kit (Affymetrix, Inc., Santa 
Clara, CA, USA) according to the manufacturer’s recommended protocol. Fragmented and 
labelled cRNA (7.5 µg) was hybridized to an Affymetrix Mouse MG-430 PM Array Strip 
(Affymetrix) for 16 h at 45°C. The strips were washed and stained using a GeneAtlas Fluidics 
Station 400 (Affymetrix), and the resulting images were scanned using a GeneAtlas Imaging 
Station (Affymetrix). Probe-level analysis, including background subtraction and quantile 
normalization, was conducted using the robust multi-array average algorithm (RMA) with 
Affymetrix Expression Console Software 1.4 (Affymetrix). The gene expression profile of the 
novel NASH model was compared with that of the HF group. Genes showing a more than two-
fold increase in expression were classified as upregulated genes and less than 0.5 fold decrease in 
expression were classified as downregulated. 
 
3-8. Statistical analysis 
All data are expressed as the means ± standard deviation. Statistical analyses were 
conducted using PRISM. Inter-group differences were assessed by one-way analysis of variance 
(ANOVA) with the Holm-Sidak post-test. Pairwise comparisons of the ITT results were 
performed using Student’s t-test. In all cases, p values less than 0.05 were considered to indicate 
statistical significance. 
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4. Results 
 
4-1. The novel NASH model developed liver injury, dyslipidaemia and hypercytokinaemia 
Findings at laparotomy and gross appearance of the liver 
There was no findings of necrosis or inflammation at the intraperitoneal injection site. 
The livers of the novel NASH model group indicated a whitish colour and an uneven surface that 
could be recognized even with the naked eye and was markedly enlarged relative to the other 
groups (Figure 2A).  
 
Body and liver weight 
Table 1 indicates the body weights, liver weights and liver-to-body weight ratios of the 
mice. The final body weight was increased in all the groups relative to the initial body weight. 
The final and initial body weight in the CCl4 group and the novel NASH group was nearly to the 
mice fed the normal diet. The liver weight and liver-to-body weight ratio were significantly 
higher in the novel NASH model group than in the other groups. 
 
Serum parameters 
Table 1 indicates the serum parameters responsible for liver injury, lipid metabolism and 
inflammatory cytokines in mice. The serum ALT and AST levels were significantly increased in 
the HF+CCl4 group relative to the other groups and increased in the novel NASH model group 
relative to the HF and HF+T0901317 groups. Furthermore, the serum TG level was significantly 
increased in the novel NASH model group relative to the other groups. The serum TNF-α and 
IL-6 concentrations were measured as indicators of circulating inflammation, and their levels 
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were significantly higher in the novel NASH model group relative to the other groups. 
 
4-2. Liver expression of genes involved in lipid metabolism 
Figure 2B indicates the mRNA levels of Srebp-1c, Fas and ApoB. Srebp-1c and Fas are 
related to de novo lipogenesis in the liver, whereas ApoB is related to lipid transport in the liver. 
The mRNA expression levels of Srebp-1c and Fas were significantly upregulated in the 
HF+T0901317 and novel NASH model groups relative to the HF and HF+CCl4 groups. The 
mRNA expression level of ApoB was significantly downregulated in the novel NASH model 
group relative to the other groups. 
 
4-3. Insulin sensitivity 
Insulin resistance was evaluated using the ITT. The glucose level after insulin injection 
remained high in the novel NASH model group (Figure 3A). The glucose level measured in the 
novel NASH model group was significantly higher than that of the HF group at 60 min, 90 min 
and 120 min, and the area under the curve (AUC) of the novel NASH model group was 
significantly higher than that of the HF group (Figure 3B). 
 
4-4. Histological findings 
Figure 4A indicates the liver histology of each group. The novel NASH model group 
developed macrovesicular hepatic steatosis, ballooning hepatocyte with Mallory-Denk bodies, 
lobular inflammation and bridging fibrosis (Figure 4B). In the novel NASH group, hepatic 
steatosis was found in the whole liver. The steatosis area in the liver was significantly larger in 
the novel NASH model group relative to the other groups (Figure 4C). In the novel NASH 
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group, the lobular inflammation was found in zone 1 in the liver and the hepatic fibrosis was 
found from zone 1 to zone 3. The values of all mice in the novel NASH model group were more 
than 5 that is diagnostic criteria of NASH. The average values of the NAS and the stage of 
hepatic fibrosis obtained for the novel NASH model group were 6.6 and 2.6, respectively, and 
both values were significantly higher than those found for the other groups (Figure 4D). 
 
4-5. Liver expression of genes involved in NASH 
Table 2 indicates the results of the microarray analysis. Eight genes were significantly 
upregulated and five genes were significantly downregulated in the novel NASH group. Five 
genes (Gstm3, Scd1. Scd2, Ly6d, and Lepr) related to NASH were detected. Furthermore, the 
expression of these five genes in all the groups was further confirmed by real-time PCR. The 
mRNA expression levels of all the tested genes were significantly upregulated in the novel 
NASH model group relative to the other groups (Figure 5). 
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5. Discussion 
Although several NASH models have been reported, few models fully reflect the 
histopathology and pathophysiology of human NASH.7-11 The MCD model and the HF diet 
model have been widely used for basic studies of NASH. However, these models do not closely 
resemble human NASH in terms of histopathological findings and insulin resistance.2 In this 
study, we established a novel experimental NASH model using a combination of an HF diet, 
CCl4 and T0901317, and the novel model exhibits similar histopathology and pathophysiology to 
human NASH. Specifically, macrovesicular hepatic steatosis, ballooning hepatocytes, Mallory-
Denk bodies, lobular inflammation and bridging fibrosis were observed in our novel NASH 
model. These manifestations are similar to those found in human NASH. Additionally, this 
model exhibited metabolic abnormalities such as insulin resistance and dyslipidaemia. These 
features are the essential requisites for an ideal NASH model.15 Although CCl4 is usually used in 
the classical hepatic fibrotic model and is administered at 1mL/kg, it is too much as a NASH 
model. Thus, I adjusted the dosage of CCl4 to 0.1mL/kg. My novel NASH model led to 
steatohepatitis with severe hepatic fibrosis in the short term. Furthermore, this model also 
developed insulin resistance. Thus, this model is expected to be useful for basic research on 
NASH. 
To date, the pathogenesis of NASH has not been completely elucidated. The ‘two-hit’ 
theory is the most widely used to explain the pathogenesis and progression of NASH; the first hit 
causes fat accumulation in hepatocytes, and the second hit causes inflammation and fibrosis.21 
However, the pathogenesis of NASH is too complex to be completely explained by this theory. 
Although the pathogenesis of NASH remains poorly understood, proinflammatory cytokines 
appear to play an important role in the development of NASH,22 with TNF-α and IL-6 showing 
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strong involvement in NASH pathogenesis.22 In a clinical setting, the serum TNF-α and IL-6 
levels are significantly increased in NASH relative to simple steatosis.23 This finding suggests 
that high serum TNF-α and IL-6 levels are involved in the development of NASH. Tomita et al. 
reported that the serum TNF-α level is a predictor of NASH.24 In this study, I found that the 
serum TNF-α and IL-6 levels are significantly increased in the novel NASH model group. These 
factors are important components of an ideal NASH model. 
Fat accumulation in hepatocytes plays a central role in the progression of NASH.25 This 
accumulation occurs when the rate of fatty acid import exceeds the rate of export. In my model, 
the following mechanisms appear to contribute to lipid accumulation in the liver: (1) an HF diet 
increases the uptake of fatty acids by hepatocytes; (2) the administration of T0901317 increases 
de novo fatty acid and triglyceride synthesis in the liver; and (3) the rates of very-low-density 
lipoprotein (VLDL) synthesis and triglyceride export are decreased. This study demonstrated that 
the mRNA expression of Srebp-1c and Fas (a marker of de novo fatty acids synthesis) was 
upregulated in the two groups administered T0901317. In contrast, the mRNA expression of 
ApoB (a marker of triglyceride export) was downregulated in only the novel NASH model group. 
Although the detailed mechanism remains unclear, increased de novo fatty acid synthesis and 
decreased triglyceride export promote fat accumulation in the liver. These effects might have 
played a key role in the progression of NASH in our model. Further studies are necessary to 
clarify the precise pathogenesis of NASH. 
In additional to the histopathological findings, insulin resistance is an important feature 
of human NASH. In fact, insulin resistance is a frequent finding in NASH patients despite the 
absence of overt diabetes and is known to play a significant role in obesity-related metabolic 
disturbances.26 I used the ITT to evaluate insulin resistance27 and found that the novel NASH 
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model developed prominent overall insulin resistance. Several in vitro studies have demonstrated 
that IL-6 promotes insulin resistance,28-31 and studies in animal models have also shown a 
correlation between IL-6 and insulin resistance.32,33 The increased serum level of IL-6 observed 
in my model might have influenced the development of insulin resistance. 
I performed a microarray analysis for the evaluation of gene expression in the novel 
NASH model and found that several genes were upregulated in the novel NASH model group 
relative to the HF group. Furthermore, I confirmed that five genes (Gstm3, Scd1, Scd2, Ly6d, and 
Lepr) related to NASH were significantly upregulated in the novel NASH model group relative 
to the other groups. Gstm3 is related to oxidative stress, and oxidative stress induced by the 
overproduction of reactive oxygen species (ROS) is necessary for the development of NASH.21,34 
Glutathione S-transferases (GSTs), including Gstm3, detoxify xenobiotics.35 Thus, the 
upregulation of this gene suggests that ROS are overproduced in mice. Scd1 and Scd2 are related 
to lipogenesis and have been shown to be upregulated in NASH animal models.36 Leptin is 
involved in the pathogenesis of NASH due to its important modulatory effects on the regulation 
of body weight and appetite and in preventing fat accumulation in the liver.37 Medici et al. 
reported that the soluble leptin receptor (SLR) is positively correlated with the stage of hepatic 
fibrosis in humans.38 Guillén et al. reported that Ly6d gene expression is positively correlated 
with hepatic steatosis in animals.39 Thus, several genes related to the development of NASH 
were found to be upregulated in the novel NASH model group. This finding supports the 
conclusion that my model exhibits the transcriptomic features of NASH.  
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6. Conclusion 
In conclusion, a novel experimental NASH model was established through feeding an HF 
diet and administering both CCl4 and T0901317 to mice. Figure 6 indicates the mechanism of the 
progression of NASH in the novel animal model. NASH is diagnosed based on histological 
findings, and clinical insulin resistance and hypercytokinaemia play central roles in its 
progression. The novel NASH model exhibits these important features and the associated 
transcriptomic characteristics. I believe that our animal model, which has the characteristics of 
human NASH, will be useful for basic research on NASH.  
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7. Tables and Figures 
 
 
 
 
 
 
 
 
Figure 1. A schematic illustrating the protocol of novel NASH model.  
The mice in the novel NASH model group were fed an HF diet for 25 days and administered 
CCl4 intraperitoneally twice a week for the final two weeks (day 14, 17, 21 and 24), and 
T0901317 intraperitoneally once a day for the final five days (from day 20 to day 24). The mice 
were sacrificed twenty-four hours after the final administration of CCl4 or T0901317.  
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Figure 2. Macroscopic changes of the liver and changes in the expression of genes involved 
in lipid metabolism in the liver.  
A: Photographs of liver tissue. Upper panel, photographs taken at laparotomy; lower panel, 
photographs taken immediately after removal (bar length = 1 cm).  
B: Parameters of lipid metabolism. (a) mRNA expression of Srebp-1c in the liver. (b) mRNA 
expression of Fas in the liver. (c) mRNA expression of ApoB in the liver. The data are expressed 
as the means ± SDs (n = 5). ** p<0.01 vs the HF and HF + CCl4 groups; ## p<0.01 vs the other 
groups.  
doi: 10.1111/pin.12612 
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Table 1. Body weight, liver weight and plasma biochemical parameters.  
 
 
HF HF+CCl4 HF+T0901317 Novel NASH model 
Body weight (g) 
    
 Initial 23.2 ± 1.1 22.9 ± 0.8 22.3 ± 0.5 22.4 ± 0.4 
 Final 31.7 ± 1.8 30.4 ± 0.9 27.6 ± 1.1** 27.0 ± 1.8** 
Liver weight (g) 1339 ± 151 1546 ± 128 1798 ± 167** 2491 ± 253** 
Liver/body weight (%) 4.24 ± 0.49 5.08 ± 0.33* 6.50 ± 0.51** 9.21 ± 0.37** 
Biochemical parameters 
    
 ALT (U/L) 58.3 ± 47.4 1425 ± 347.4## 83.7 ± 30.6 739.6 ± 494.2** 
 AST (U/L) 79.2 ± 39.6 613.8 ±139.9** 107.7 ± 27.4 620.8 ± 251.4** 
 TG (mg/dL) 128.8 ± 22.3 145.2 ± 46.2 172.2 ± 35.3 509.4 ± 252.3## 
 T-CHO (mg/dL) 129.3 ± 10.5 157.5 ± 14.8** 198.7 ± 6.1** 125.4 ± 18.2 
Inflammatory parameters 
    
 TNF-α (pg/mL) 4.72 ± 2.88 5.30 ± 0.93 3.56 ± 0.64 10.80 ± 3.48## 
 IL-6 (pg/mL) 4.79 ± 2.06 23.65 ± 9.41 11.60 ± 6.67 372.12 ± 107.36## 
 
Note: Data are mean ± SD (n = 5). * < 0.05, ** <0.01 vs HF group (control). ## < 0.01 vs other 
groups. 
 
doi: 10.1111/pin.12612 
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Figure 3. Evaluation of insulin sensitivity.  
A: Results of insulin tolerance test.  
B: Area under the curve. The data are expressed as the means ± SDs (n = 5). *p<0.05 for the 
comparison of the novel NASH model group vs the HF group.  
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Figure 4. Histopathological findings.  
A: Representative liver histopathology. Upper panel, the results of haematoxylin and eosin 
staining; upper middle panel, the results of Masson’s trichrome staining; lower middle panel, the 
results of Sirius red staining; lower panel, the results of Oil Red O staining. (Original 
magnification ×200 in HE, MT and SR, ×400 in OR).  
B: Representative liver histopathological findings of haematoxylin and eosin staining and Oil red 
O staining of the novel NASH model group: (a) hepatocyte ballooning, (b) Mallory-Denk bodies, 
(c) inflammation and (d) macrovesicular steatosis.  
C: Rate of hepatic steatosis area as indicated by Oil Red O staining in each group. The data are 
expressed as the means ± SDs (n = 5). **** p<0.0001 vs the other groups.  
D: Histopathological evaluation of the liver based on the NAFLD activity score (NAS; 0-8 
points). The scoring was based on the presence of steatosis (0-3 points), inflammation (0-3 
points) and ballooning (0-2 points). NASH was diagnosed when the number of total points 
exceeded 5. Fibrosis of the liver was evaluated by the Kleiner classification (0-3 points). Each 
group included n = 5. 
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Table 2. Microarray analysis of liver tissues from mice in the novel NASH model group and 
HF group 
 
Relation Gene 
Symbol 
Gene Name (Description) Fold 
change 
P-value Regulation 
 CYP4A11 Cytochrome P450, family 4, subfamily A, 
polypeptide 11 
2.78 0.005 Up 
Oxidative 
stress 
Gstm3 glutathione S-transferase mu 3 2.69 0.013 Up 
Lipogenesis Scd2 Stearoyl-CoA desaturase 
(delta-9-desaturase) 
2.67 0.001 Up 
 RAD51B RAD51 paralog B 2.34 0.007 Up 
Hepatic 
fibrosis 
LEPR leptin receptor 2.28 0.025 Up 
Hepatic 
steatosis 
LY6D lymphocyte antigen 6 complex, locus D 2.26 0.001 Up 
Lipogenesis Scd1 Stearoyl-CoA desaturase 
(delta-9-desaturase) 
2.09 0.003 Up 
 BIRC5 baculoviral IAP repeat containing 5 2.03 0.016 Up 
 MOXD1 monooxygenase, DBH-like 1 0.47 0.041 Down 
 m_150001
7E21Rik 
RIKEN cDNA 1500017E21 gene 0.47 0.002 Down 
 m_Serpina
4-ps1 
serine (or cysteine) peptidase inhibitor, 
clade A, member 4, pseudogene 
0.47 0.041 Down 
 UGT2B28 UDP glucuronosyltransferase 2 family, 
polypeptide B28 
0.46 0.002 Down 
 m_Mup3 Major urinary protein 3 0.45 0.001 Down 
 
Note: Liver samples from two mice in the novel NASH model group and HF group were used 
for the microarray analysis. Five genes related to NASH were upregulated in the novel NASH 
model group more than 2-fold compared to the corresponding genes in the HF group. 
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Figure 5. Genes involved in NASH development that were upregulated in the microarray 
analysis.  
(A) mRNA expression of Gsmt3 in the liver. (B) mRNA expression of Scd1 in the liver. (C) 
mRNA expression of Scd2 in the liver. (D) mRNA expression of Ly6d in the liver. (E) mRNA 
expression of Lepr in the liver. The data are expressed as the means ± SDs (n = 5). ** p<0.01 vs 
the other groups.  
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Figure 6. A schematic illustrating the progression of NASH in the novel animal model. 
Fat accumulation in hepatocytes plays a central role in the progression of NASH. The 
administration of T0901317, a liver X receptor agonist, promotes de novo lipogenesis in the 
liver. In addition, a HF diet increases the uptake of fatty acids. On the other hand, ApoB, a 
marker of triglyceride export, was downregulated in the novel NASH model, which resulted in 
the development of hepatic steatosis. Excess FFAs in the liver causes FFA oxidation and 
consequent induction of oxidative stress. Administration of CCl4 induces oxidative stress as well. 
Elevated levels of oxidative stress cause inflammation and fibrosis, and the recruitment of 
proinflammatory cytokines in response to oxidative stress promotes insulin resistance.  
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